Max Healthcare Q1FY27 network PAT rises 3% to ₹357 crore on volume growth
Max Healthcare reported Q1FY27 network PAT of ₹357 crore, up 3% YoY, with gross revenue rising 16% to ₹2,982 crore. The growth was supported by the inclusion of Kalinga Hospital Limited and strong performance across Max Lab and Max@Home verticals. Operating EBITDA margin dipped slightly to 24.8% due to higher overheads from new units, while free cash flow of ₹397 crore funded recent acquisitions and capex plans.
*this image is generated using AI for illustrative purposes only.
The board of directors at Max Healthcare Institute approved its unaudited consolidated financial results for the quarter ended June 30, 2026, on August 13, 2026. The healthcare services provider reported robust top-line growth, with network gross revenue rising 16% year-on-year to ₹2,982 crore from ₹2,574 crore in the corresponding quarter of FY25. This growth was supported by the inclusion of Kalinga Hospital Limited (KHL), acquired in May 2026, and strong operational performance across existing facilities. Net revenue stood at ₹2,835 crore, reflecting a 15% YoY increase.
Consolidated net profit after tax (PAT) for the quarter stood at ₹322.96 crore, marking a 4.9% increase from ₹307.97 crore in Q1FY25. However, the broader network PAT, which includes partner healthcare facilities, grew by 3% YoY to ₹357 crore from ₹345 crore. This moderation in profit growth relative to revenue was primarily due to increased depreciation and finance costs consequent to the commissioning of brownfield capacity expansions at MSSH Mohali, Nanavati-Max, and Max Smart, as well as the acquisition of KHL.
Financial Performance Highlights
| Metric: | Q1FY27 Network: | Q1FY26 Network: | Change: |
|---|---|---|---|
| Gross Revenue: | ₹2,982 crore | ₹2,574 crore | +16% |
| Net Revenue: | ₹2,835 crore | ₹2,460 crore | +15% |
| Operating EBITDA: | ₹704 crore | ₹613 crore | +15% |
| Operating EBITDA Margin: | 24.8% | 24.9% | -10 bps |
| Network PAT: | ₹357 crore | ₹345 crore | +3% |
| Consolidated PAT: | ₹322.96 crore | ₹307.97 crore | +4.9% |
What the Numbers Show
A key divergence in the quarter’s results is the disparity between revenue growth and margin stability. While gross revenue grew 16%, operating EBITDA margin contracted slightly to 24.8% from 24.9% in Q1FY26. This compression was driven by higher indirect overheads, which included ₹195 crore for new units including KHL. However, excluding oncology revenues—which dropped due to the discontinuation of select chemotherapy drugs for institutional patients—gross revenue grew by 20% YoY. This indicates that core operational volumes remained strong despite structural changes in high-value drug billing. Additionally, free cash from operations stood at ₹397 crore, with ₹386 crore deployed towards the acquisitions of KHL and Yerawada Properties Private Limited (YPPL), highlighting the company’s aggressive M&A strategy.
Segment Performance and Vertical Growth
Max Lab, the non-captive pathology vertical, reported gross revenue of ₹58 crore, recording a 20% YoY and 11% QoQ growth. Services are now available across 60+ cities. Max@Home reported gross revenue of ₹78 crore, reflecting a 32% YoY and 7% QoQ growth, driven by physio & rehab, nursing care, and transactional services.
MSSH Bhubaneswar (erstwhile Kalinga Hospital) contributed ₹19 crore in revenue and ~₹2 crore in EBITDA during the post-acquisition period in Q1FY27, with 50% occupancy and an average revenue per occupied bed (ARPOB) of ₹35,000. Prior to acquisition, the hospital generated revenue of ~₹154 crore in FY26.
Capital Expenditure and Expansion
The board approved a capital expenditure of ₹425 crore for the expansion of Max Super Speciality Hospital, Vaishali. The funds will be utilized for the construction of ‘Tower 3’ on an adjacent ~1-acre land parcel, adding approximately 202 census beds to the existing capacity of 387 beds. The project is expected to be commissioned by Q4 FY30. Additionally, 202 beds in the brownfield tower of Max Smart Super Speciality Hospital have been operationalized, with the remaining 198 beds expected to be handed over in Q2FY27.
Management Changes
Max Healthcare announced changes in its senior management team:
- Mr. Ajay Vij has been appointed as Director - Chief Supply Chain & Procurement Officer, effective August 14, 2026.
- Mr. Pawan Kumar Marella has been appointed as Senior Director - Chief Experience & Brand Officer, effective August 17, 2026.
- Dr. N. Venkatesan, Senior Director & Chief Procurement Officer, resigned to pursue other opportunities and will cease to be part of the senior management effective August 31, 2026.
S.R. Batliboi & Co. LLP, the statutory auditors, issued an unmodified limited review report on the financial results.
Historical Stock Returns for Max Healthcare Institute
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.58% | -6.18% | -8.40% | -4.67% | -19.62% | +207.48% |
How will the integration of Kalinga Hospital Limited impact Max Healthcare's long-term EBITDA margins once the initial acquisition-related overheads normalize?
What is the expected timeline for the newly commissioned brownfield capacity at MSSH Mohali and Nanavati-Max to achieve full occupancy and break-even profitability?
Given the 20% YoY growth in Max Lab and Max@Home, will these non-hospital verticals become significant profit centers independent of core hospital operations in the coming fiscal years?
18
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
